Alloreactivity and apoptosis in graft rejection and transplantation tolerance

Journal of Leukocyte Biology

Volumn 68, Issue 2, 2000, Pages 167-174

  Zavazava, N ^a   Kabelitz, D ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Fas ligand(FasL) CD95 L; Fas CD95; Peripheral tolerance; Programmed cell death; Soluble MHC

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ALLOIMMUNITY; APOPTOSIS; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REVIEW; THYMUS; TRANSPLANTATION;

ANIMALS; APOPTOSIS; GRAFT REJECTION; HUMANS; ISOANTIGENS; ORGAN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 0033857153     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
2. Indirect presentation of MHC antigens in transplantation
3. Summary report from the first international workshop on soluble HLA antigens, Paris, August 1992
4. Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients
5. Th1 and Th2 cytokines in organ transplantation: Paradigm lost?
6. Tolerance induction by anti-CD2 plus anti-CD3 monoclonal antibodies: Evidence for an IL-4 requirement
7. Treatment with interleukin-4 prolongs allogeneic neonatal heart graft survival by inducing T helper 2 responses
8. The role of peptides in T cell alloreactivity is determined by self-major histocompatibillty complex molecules
9. A naturally processed peptide presented by HLA-A;s*0201 is expressed at low abundance and recognized by an alloreactive CD8+ cytotoxic T cell with apparent high affinity
10. The same natural ligand is involved in allorecognition of multiple HLA-B27 subtypes by a single T cell clone: Role of peptide and the MHC molecule in alloreactivity
11. Class I-restricted alloreactive cytotoxic T lymphocytes recognize a complex array of specific MHC-associated peptides
12. Peptide-Independent recognition by alloreactive cytotoxic T lymphocytes (CTL)
13. An α3 T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex
14. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2
15. The molecular basis of alloreactivity
16. Minor histocompatibility antigens, defined by graft-vs.-host disease-derived cytotoxic T lymphocytes, show variable expression on human skin cells
17. The role of human minor histocompatibility antigens in graft failure: A mini-review
18. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease
19. Identification of a graft versus host disease-associated human minor histocompatibility antigen
20. Functional significance of two cytolytic pathways of cytotoxic T lymphocytes
21. The Fas death factor
22. The biochemistry of programmed cell death
23. Prognostic value of lymphocyte apoptosis in acute rejection of renal allografts
24. Apoptosis within spontaneously accepted mouse liver allografts
25. Molecules involved in cell death and peripheral tolerance
26. Lymhoproliferation disorder in mice explained by defects in fas antigen that mediates apoptosis
27. Two signalling pathways can lead to Fas ligand expression in CD8+ cytotoxic T lymphocyte clones
28. Generation of lymphoproliferative disease caused by a point mutation in the fas ligand
29. Mutations in fas associated with human lymphoproliferative syndrome and autoimmunity
30. A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity
31. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes
32. Granzyme A-deficient mice retain potent cell-mediated cytotoxicity
33. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis
34. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia
35. Immunological Tolerance
36. Fas ligand-induced apoptosis as a mechanism of immune privilege
37. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance
38. A role of CD95 ligand in preventing graft rejection
39. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response
40. Mechanism of lymphocyte-mediated cytotoxicity
41. Fas involvement in calcium-independent T cell-mediated cytotoxicity
42. Kinetics and efficacy of positive selection in the thymus of normal and T cell receptor transgenic mice
43. Anti-bodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures
44. Apoptosis, graft rejection and transplantation tolerance
45. Immunosuppression by OKT3-induction of programmed cell death (apoptosis) as a possible mechanism of action
46. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes
47. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas
48. Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death inducing signalling complex
49. CD28/B7 costimulation: A review
50. Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy
51. Inhibition of transplant rejection folowing treatment with anti-B7-2 and anti-B7-1 antibodies
52. CTLA-4 is a second receptor for the B cell activation antigen B7
53. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
54. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in non-human primates
55. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction
56. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts
57. Antitumor effect of locally produced CD95 ligand
58. Regulation of the proinflammatory effects of Fas ligand (CD95L)
59. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance
60. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
61. Fully allogeneic liver grafting and the induction of donor-specific unreactivity
62. High levels of donor HLA antigens in the circulation of human liver graft recipients
63. Peroperative appearance of serum class I antigens during liver transplantation
64. Soluble HLA class I molecules: Biological signifcance and clinical implications
65. Tolerance to rat liver allografts III. Donor cell migration and tolerance-associated cytokine production in peripheral lymphoid tissues
66. High-dose/activation-associated tolerance
67. Tolerance to rat liver allografts: IV. Acceptance depends on the quantity of donor tissue and on donor leukocytes
68. Intravenous injection of soluble antigen induces thymic and peripheral T-cell apoptosis
69. TcR-mediated internalization of peptide-MHC complexes acquired by T cells
70. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetraneric major histocompatibility complex class I-peptide complexes
71. T cell priming versus T cell tolerance induced by synthetic peptides
72. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes
73. + T cells by the normal liver
74. Soluble HL-A7 antigen: Localization in the β-lipoprotein fraction of human serum
75. Anti HL-A2 inhibitor in normal human serum
76. Immunogenicity of serum HLA antigens in allogeneic combinations
77. Biologic and chemical characterization of HLA antigens in human serum
78. T cell activation by purified, soluble, class I MHC molecules
79. Inhibition of an allospecific T cell hybridoma by soluble class I proteins and peptides: Estimation of the affinity of a T cell receptor for MHC
80. Inhibition of anti-HLAB7 alloreactive CTL by affinity purified soluble HLA
81. Interaction of papain-digested HLA class I molecules with human alloreactive cytotoxic T lymphocytes (CTL)
82. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
83. Antigen-induced death of alloreactive human T-lymphocytes occurs in the absence of low molecular weight DNA fragmentation
84. The fate of adoptively transferred antigen-specific T cells in vivo
85. + T lymphocytes
86. Antigen-induced death of mature T lymphocytes
87. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis
88. Single-chain MHC class II molecules induce T cell activation and apoptosis
89. Antigen-specific apoptosis in immortalized T cells by soluble MHC class-II peptide complexes
90. Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis
91. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
92. Apoptotic pathways: The roads to ruin
93. Direct MHC class I complementary DNA transfer to thymus induces donor-specific unresponsiveness, which involves multiple immunologic mechanisms